Lipid mediator profiling in pulmonary disease

Current Pharmaceutical Biotechnology

Volumn 12, Issue 7, 2011, Pages 1026-1052

  Lundström, Susanna L ^a   Balgoma, David ^a   Wheelock, Åsa M ^a   Haeggström, Jesper Z ^a   Dahlén, Sven Erik ^a   Wheelock, Craig E ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Asthma; Eicosanoid; Inflammation; Lipidomics; Lung; Mass spectrometry; Metabolomics; Multivariate analysis; Oxylipin; Respiratory disease

Indexed keywords

ARACHIDONIC ACID; BIOLOGICAL MARKER; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIHYDROXYICOSATRIENOIC ACID; EOXIN; EPOXYICOSATRIENOIC ACID; HYDROXY FATTY ACID; HYDROXYICOSATETRAENOIC ACID; HYDROXYOCTADECADIENOIC ACID; LEUKOTOXIN; LEUKOTRIENE; LINOLEIC ACID; LIPOXIN; OXOEICOSATETRAENOIC ACID; OXOOCTADECADIENOIC ACID; OXYLIPIN; POLYUNSATURATED FATTY ACID; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN E2; PROTEIN; THROMBOXANE; THROMBOXANE A2; TRIHYDROXYOCTADECENOIC ACID; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; COLLISIONALLY ACTIVATED DISSOCIATION; CORRELATIONAL STUDY; ELECTROSPRAY; FATTY ACID METABOLISM; HUMAN; INFORMATION PROCESSING; LIQUID CHROMATOGRAPHY; LUNG DISEASE; MASS SPECTROMETRY; METHODOLOGY; NONHUMAN;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; LIPID METABOLISM; LIPIDS; LUNG DISEASES;

EID: 79959365799     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111795909087     Document Type: Article

References (360)

1. Braman, S.S. The global burden of asthma. Chest, 2006, 130(1 Suppl), 4S-12S.
2. Sullivan, S.D.; Weiss, K.B. Health economics of asthma and rhinitis. II. Assessing the value of interventions. J.Allergy Clin. Immunol., 2001, 107(2), 203-210.
3. Pauwels, R.A.; Buist, A.S.; Calverley, P.M.; Jenkins, C.R.; Hurd, S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med., 2001, 163(5), 1256-1276.
4. Pauwels, R.A.; Rabe, K.F. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet, 2004, 364(9434), 613-620.
5. Donnelly, L.E.; Rogers, D.F. Novel targets and drugs in inflammatory lung disease. Curr. Opin. Pharmacol., 2008, 8(3), 219-221.
6. Barnes, P.J. Pathophysiology of asthma. Br. J. Clin. Pharmacol., 1996, 42(1), 3-10.
7. Lemanske, R.F. Jr.; Busse, W.W. 6. Asthma. J. Allergy Clin. Immunol., 2003, 111(2 Suppl), S502-519.
8. Holgate, S.T. Pathogenesis of asthma. Clin. Exp. Allergy, 2008, 38(6), 872-897.
9. Barnes, P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol., 2008, 8(3), 183-192.
10. Larsson, K. Aspects on pathophysiological mechanisms in COPD. J. Intern. Med., 2007, 262(3), 311-340.
11. Salvi, S.S.; Barnes, P.J. Chronic obstructive pulmonary disease in non-smokers. Lancet, 2009, 374(9691), 733-743.
12. Chanez, P.; Wenzel, S.E.; Anderson, G.P.; Anto, J.M.; Bel, E.H.; Boulet, L.P.; Brightling, C.E.; Busse, W.W.; Castro, M.; Dahlen, B.; Dahlen, S.E.; Fabbri, L.M.; Holgate, S.T.; Humbert, M.; Gaga, M.; Joos, G.F.; Levy, B.; Rabe, K.F.; Sterk, P.J.; Wilson, S.J.; Vachier, I. Severe asthma in adults: what are the important questions? J. Allergy Clin. Immunol., 2007, 119(6), 1337-1348.
13. Nordstrom, A.; Lewensohn, R. Metabolomics: moving to the clinic. J. Neuroimmune Pharmacol., 2010, 5(1), 4-17.
14. Ceglarek, U.; Leichtle, A.; Brugel, M.; Kortz, L.; Brauer, R.; Bresler, K.; Thiery, J.; Fiedler, G.M. Challenges and developments in tandem mass spectrometry based clinical metabolomics. Mol. Cell. Endocrinol., 2009, 301(1-2), 266-271.
15. Dunn, W.B.; Broadhurst, D.I.; Atherton, H.J.; Goodacre, R.; Griffin, J.L. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spec-troscopy. Chem. Soc. Rev., 2010, 40(1), 387-426
16. Oliver, S.G.; Winson, M.K.; Kell, D.B.; Baganz, F. Systematic functional analysis of the yeast genome. Trends Biotechnol., 1998, 16(9), 373-38.
17. Griffiths, W.J.; Koal, T.; Wang, Y.; Kohl, M.; Enot, D.P.; Deigner, H.P. Targeted metabolomics for biomarker discovery. Angew. Chem. Int. Ed. Engl., 2010, 49(32), 5426-5445.
18. Koal, T.; Deigner, H.P. Challenges in mass spectrometry based targeted metabolomics. Curr. Mol. Med., 2010, 10(2), 216-226.
19. Gerwick, W.H.; Moghaddam, M.; Hamberg, M. Oxylipin metabolism in the red alga Gracilariopsis lemaneiformis: mechanism of formation of vicinal dihydroxy fatty acids. Arch. Biochem. Biophys, 1991, 290(2), 436-444.
20. Conrad, D.J. The arachidonate 12/15 lipoxygenases. A review of tissue expression and biologic function. Clin. Rev. Allergy Immunol., 1999, 17(1-2), 71-89.
21. Funk, C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science, 2001, 294(5548), 1871-1875.
22. Samuelsson, B.; Dahlen, S.E.; Lindgren, J.A.; Rouzer, C.A.; Ser-han, C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science, 1987, 237(4819), 1171-1176.
23. Boyce, J.A. Eicosanoids in asthma, allergic inflammation, and host defense. Curr. Mol. Med., 2008, 8(5), 335-349.
24. Higashi, A.; Higashi, N.; Tsuburai, T.; Takeuchi, Y.; Taniguchi, M.; Mita, H.; Saito, A.; Takatori, K.; Arimura, K.; Akiyama, K. Involvement of eicosanoids and surfactant protein D in extrinsic allergic alveolitis. Eur. Respir. J., 2005, 26(6), 1069-1073.
25. Dahlen, S.E.; Hedqvist, P.; Hammarstrom, S.; Samuelsson, B. Leukotrienes are potent constrictors of human bronchi. Nature, 1980, 288(5790), 484-486.
26. Levy, B.D. Lipoxins and lipoxin analogs in asthma. Prostaglandins Leukot Essent Fatty Acids, 2005, 73(3-4), 231-237.
27. Hao, C.M.; Breyer, M.D. Roles of lipid mediators in kidney injury. Semin. Nephrol., 2007, 27(3), 338-351.
28. Roman, R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev., 2002, 82(1), 131-185.
29. Natarajan, R.; Nadler, J.L. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc. Biol., 2004, 24(9), 1542-1548.
30. Shearer, G.C.; Newman, J.W. Impact of circulating esterified ei-cosanoids and other oxylipins on endothelial function. Curr. Athe-roscler Rep., 2009, 11(6), 403-410.
31. Nie, D.; Tang, K.; Szekeres, K.; Trikha, M.; Honn, K.V. The role of eicosanoids in tumor growth and metastasis. Ernst Schering Res. Found Workshop, 2000, 31, 201-217.
32. Chung, K.F. Evaluation of selective prostaglandin E2 (PGE2) receptor agonists as therapeutic agents for the treatment of asthma. Sci STKE, 2005, 2005(303), pe47.
33. Sala, A.; Folco, G.; Murphy, R.C. Transcellular biosynthesis of eicosanoids. Pharmacol. Rep., 2010, 62(3), 503-510.
34. Sanak, M.; Levy, B.D.; Clish, C.B.; Chiang, N.; Gronert, K.; Mastalerz, L.; Serhan, C.N.; Szczeklik, A. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur. Respir. J., 2000, 16(1), 44-49.
35. Newman, J.W.; Watanabe, T.; Hammock, B.D. The simultaneous quantification of cytochrome P450 dependent linoleate and arachi-donate metabolites in urine by HPLC-MS/MS. J. Lipid. Res., 2002, 43(9), 1563-1578.
36. Schmelzer, K.R.; Wheelock, A.M.; Dettmer, K.; Morin, D.; Hammock, B.D. The role of inflammatory mediators in the synergistic toxicity of ozone and 1-nitronaphthalene in rat airways. Environ. Health Perspect., 2006, 114(9), 1354-1360.
37. Song, W.L.; Lawson, J.A.; Wang, M.; Zou, H.; FitzGerald, G.A. Noninvasive assessment of the role of cyclooxygenases in cardiovascular health: a detailed HPLC/MS/MS method. Methods Enzy-mol., 2007, 433, 51-72.
38. Jakobsson, P.J.; Thoren, S.; Morgenstern, R.; Samuelsson, B. Identification of human prostaglandin E synthase: a microsomal, glu-tathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. USA, 1999, 96(13), 7220-7225.
39. Samuelsson, B.; Morgenstern, R.; Jakobsson, P.J. Membrane pros-taglandin E synthase-1: a novel therapeutic target. Pharmacol. Rev., 2007, 59(3), 207-224.
40. Smyth, E.M.; Grosser, T.; Wang, M.; Yu, Y.; FitzGerald, G.A. Prostanoids in health and disease. J. Lipid Res., 2009, 50 (Suppl), S423-428.
41. Selg, E.; Andersson, M.; Lastbom, L.; Ryrfeldt, A.; Dahlen, S.E. Two different mechanisms for modulation of bronchoconstriction in guinea-pigs by cyclooxygenase metabolites. Prostaglandins Other Lipid Mediat, 2009, 88(3-4), 101-110.
42. Harizi, H.; Juzan, M.; Moreau, J.F.; Gualde, N. Prostaglandins inhibit 5-lipoxygenase-activating protein expression and leukot-riene B4 production from dendritic cells via an IL-10-dependent mechanism. J. Immunol., 2003, 170(1), 139-146.
43. Higashi, N.; Mita, H.; Ono, E.; Fukutomi, Y.; Yamaguchi, H.; Kajiwara, K.; Tanimoto, H.; Sekiya, K.; Akiyama, K.; Taniguchi, M. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J. Allergy Clin. Immunol., 2010, 125(5), 1084-1091 e6.
44. Brussino, L.; Badiu, I.; Sciascia, S.; Bugiani, M.; Heffler, E.; Guida, G.; Malinovschi, A.; Bucca, C.; Rolla, G. Oxidative stress and airway inflammation after allergen challenge evaluated by exhaled breath condensate analysis. Clin. Exp Allergy, 2010, 40(11), 1642-1647.
45. Park, G.Y.; Christman, J.W. Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of inflammatory lung diseases. Am. J. Physiol. Lung Cell Mol. Physiol., 2006, 290(5), L797-805.
46. Guilemany, J.M.; Roca-Ferrer, J.; Mullol, J. Cyclooxygenases and the pathogenesis of chronic rhinosinusitis and nasal polyposis. Curr. Allergy Asthma Rep., 2008, 8(3), 219-226.
47. Rolin, S.; Masereel, B.; Dogne, J.M. Prostanoids as pharmacological targets in COPD and asthma. Eur. J. Pharmacol., 2006, 533(1-3), 89-100.
48. Vancheri, C.; Mastruzzo, C.; Sortino, M.A.; Crimi, N. The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol., 2004, 25(1), 40-46.
49. Martin, L.D.; Rochelle, L.G.; Fischer, B.M.; Krunkosky, T.M.; Adler, K.B. Airway epithelium as an effector of inflammation: molecular regulation of secondary mediators. Eur. Respir J., 1997, 10(9), 2139-2146.
50. Thien, F.C.K.; Walters, E.H. Eicosanoids and asthma: an update. Prostaglandins Leukot Essent Fatty Acids, 1995, 52(5), 271-288.
51. Henderson, W.R. Eicosanoids and lung inflammation. Am. Rev. Respir. Dis., 1987, 135(5), 1176-1185.
52. Holtzman, M.J. Arachidonic acid metabolism in airway epithelial cells. Annu. Rev. Physiol., 1992, 54, 303-329.
53. Hamberg, M.; Svensson, J.; Samuelsson, B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA, 1975, 72(8), 2994-8.
54. Harrington, L.S.; Lucas, R.; McMaster, S.K.; Moreno, L.; Scad-ding, G.; Warner, T.D.; Mitchell, J.A. COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. FASEB J., 2008, 22(11), 4005-4010.
55. Swedin, L.; Neimert-Andersson, T.; Hjoberg, J.; Jonasson, S.; van Hage, M.; Adner, M.; Ryrfeldt, A.; Dahlen, S.E. Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur. Respir J., 2009, 34(1), 200-208.
56. Hartert, T.V.; Dworski, R.T.; Mellen, B.G.; Oates, J.A.; Murray, J.J.; Sheller, J.R. Prostaglandin E(2) decreases allergen-stimulated release of prostaglandin D(2) in airways of subjects with asthma. Am. J. Respir Crit. Care Med., 2000, 162(2 Pt 1), 637-640.
57. Sheller, J.R.; Mitchell, D.; Meyrick, B.; Oates, J.; Breyer, R. EP(2) receptor mediates bronchodilation by PGE(2) in mice. J. Appl. Physiol., 2000, 88(6), 2214-2218.
58. Gauvreau, G.M.; Watson, R.M.; O'Byrne, P.M. Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation. Am. J. Respir. Crit. Care Med., 1999, 159(1), 31-36.
59. Schafer, D.; Lindenthal, U.; Wagner, M.; Bolcskei, P.L.; Baenkler, H.W. Effect of prostaglandin E2 on eicosanoid release by human bronchial biopsy specimens from normal and inflamed mucosa. Thorax, 1996, 51(9), 919-923.
60. Flamand, N.; Surette, M.E.; Picard, S.; Bourgoin, S.; Borgeat, P. Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol. Pharmacol., 2002, 62(2), 250-256.
61. Stevenson, D.D.; Szczeklik, A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J. Allergy Clin. Immunol., 2006, 118(4), 773-786; quiz 787-788.
62. Berges-Gimeno, M.P.; Simon, R.A.; Stevenson, D.D. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann. Allergy Asthma Immunol., 2002, 89(5), 474-478.
63. Szczeklik, A.; Gryglewski, R.J.; Czerniawska-Mysik, G. Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. J. Allergy Clin. Immunol., 1977, 60(5), 276-284.
64. Vanselow, N.A.; Smith, J.R. Bronchial asthma induced by indo-methacin. Ann. Intern Med., 1967, 66(3), 568-572.
65. Szczeklik, A.; Gryglewski, R.J.; Czerniawska-Mysik, G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br. Med. J., 1975, 1(5949), 67-69.
66. Mathison, D.A.; Stevenson, D.D. Hypersensitivity to nonsteroidal antiinflammatory drugs: indications and methods for oral challenges. J. Allergy Clin. Immunol., 1979, 64(6 pt 2), 669-674.
67. Woessner, K.M. Crossreacting drugs and chemicals. Clin. Rev. Allergy Immunol., 2003, 24(2), 149-158.
68. Profita, M.; Sala, A.; Bonanno, A.; Riccobono, L.; Ferraro, M.; La Grutta, S.; Albano, G.D.; Montalbano, A.M.; Gjomarkaj, M. Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products. Am. J. Physiol. Lung Cell Mol. Physiol., 2010, 298(2), L261-269.
69. Kostikas, K.; Koutsokera, A.; Papiris, S.; Gourgoulianis, K.I.; Loukides, S. Exhaled breath condensate in patients with asthma: implications for application in clinical practice. Clin. Exp. Allergy, 2008, 38(4), 557-565.
70. Montuschi, P.; Kharitonov, S.A.; Ciabattoni, G.; Barnes, P.J. Exhaled leukotrienes and prostaglandins in COPD. Thorax, 2003, 58(7), 585-588.
71. Montuschi, P.; Barnes, P.J. Exhaled leukotrienes and prostagland-ins in asthma. J. Allergy Clin. Immunol., 2002, 109(4), 615-620.
72. Kostikas, K.; Papatheodorou, G.; Psathakis, K.; Panagou, P.; Lou-kides, S. Prostaglandin E2 in the expired breath condensate of patients with asthma. Eur. Respir J., 2003, 22(5), 743-747.
73. Sanak, M.; Gielicz, A.; Nagraba, K.; Kaszuba, M.; Kumik, J.; Szczeklik, A. Targeted eicosanoids lipidomics of exhaled breath condensate in healthy subjects. J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 2010, 878(21), 1796-1800.
74. Hardy, C.C.; Robinson, C.; Tattersfield, A.E.; Holgate, S.T. The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. N. Engl. J. Med., 1984, 311(4), 209-213.
75. Rovati, G.E.; Sala, A.; Capra, V.; Dahlen, S.E.; Folco, G. Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk. Trends Pharmacol. Sci., 2010, 31(3), 102-107.
76. Kurosawa, M. Role of thromboxane A2 synthetase inhibitors in the treatment of patients with bronchial asthma. Clin. Ther., 1995, 17(1), 2-11; discussion 1.
77. Ciabattoni, G.; Davi, G.; Collura, M.; Iapichino, L.; Pardo, F.; Ganci, A.; Romagnoli, R.; Maclouf, J.; Patrono, C. In vivo lipid peroxidation and platelet activation in cystic fibrosis. Am. J. Respir. Crit. Care Med., 2000, 162(4 Pt 1), 1195-1201.
78. Wenzel, S.E.; Westcott, J.Y.; Larsen, G.L. Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses. J. Allergy Clin. Immunol., 1991, 87(2), 540-548.
79. Kumlin, M.; Dahlen, B.; Bjorck, T.; Zetterstrom, O.; Granstrom, E.; Dahlen, S.E. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am. Rev. Respir. Dis., 1992, 146(1), 96-103.
80. Oosterhoff, Y.; Kauffman, H.F.; Rutgers, B.; Zijlstra, F.J.; Koeter, G.H.; Postma, D.S. Inflammatory cell number and mediators in bronchoalveolar lavage fluid and peripheral blood in subjects with asthma with increased nocturnal airways narrowing. J. Allergy Clin. Immunol., 1995, 96(2), 219-229.
81. Wenzel, S.E.; Westcott, J.Y.; Smith, H.R.; Larsen, G.L. Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups. An alteration in the ratio of bronchoconstrictive to bronchoprotective mediators. Am. Rev. Respir. Dis., 1989, 139(2), 450-457.
82. Sladek, K.; Dworski, R.; Fitzgerald, G.A.; Buitkus, K.L.; Block, F.J.; Marney, S.R. Jr.; Sheller, J.R. Allergen-stimulated release of thromboxane A2 and leukotriene E4 in humans. Effect of indo-methacin. Am. Rev. Respir. Dis., 1990, 141(6), 1441-1445.
83. Davi, G.; Basili, S.; Vieri, M.; Cipollone, F.; Santarone, S.; Ales-sandri, C.; Gazzaniga, P.; Cordova, C.; Violi, F. Enhanced throm-boxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group. Am. J. Respir. Crit. Care Med., 1997, 156(6), 1794-1799.
84. Higgs, G.A.; Moncada, S.; Salmon, J.A.; Seager, K. The source of thromboxane and prostaglandins in experimental inflammation. Br. J. Pharmacol., 1983, 79(4), 863-868.
85. Nusing, R.; Lesch, R.; Ullrich, V. Immunohistochemical localization of thromboxane synthase in human tissues. Eicosanoids, 1990, 3(1), 53-58.
86. Widdicombe, J.H.; Ueki, I.F.; Emery, D.; Margolskee, D.; Yergey, J.; Nadel, J.A. Release of cyclooxygenase products from primary cultures of tracheal epithelia of dog and human. Am. J. Physiol., 1989, 257(6 Pt 1), L361-365.
87. Grosser, T.; Yu, Y.; FitzGerald, G.A. Emotion Recollected in Tranquility: Lessons Learned from the COX-2 Saga. Annu. Rev. Med., 2010, 61, 17-33.
88. Max, M.; Rossaint, R. Inhaled prostacyclin in the treatment of pulmonary hypertension. Eur. J. Pediatr., 1999, 158, S23-S26.
89. Domenighetti, G.; Stricker, H.; Waldispuehl, B. Nebulized prosta-cyclin (PGI2) in acute respiratory distress syndrome: Impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Crit. Care Med., 2001, 29(1), 57-62.
90. van Heerden, P.V.; Barden, A.; Michalopoulos, N.; Bulsara, M.K.; Roberts, B.L. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest, 2000, 117(3), 819-827.
91. Hashimoto, K.; Ishibashi, K.; Gebretsadik, T.; Hartert, T.V.; Ya-mamoto, A.; Nakayama, T.; Ohashi, K.; Sakata, H.; Kawasaki, Y.; Katayose, M.; Sakuma, H.; Suzuki, H.; Hosoya, M.; Peebles, R.S.; Suzutani, T. Functional polymorphism of the promoter region of the prostacyclin synthase gene and severity of RSV infection in hospitalized children. J. Med. Virol., 2008, 80(11), 2015-2022.
92. Soditt, V.; Aring, C.; Groneck, P. Improvement of oxygenation induced by aerosolized prostacyclin in a preterm infant with persistent pulmonary hypertension of the newborn. Intensive Care Med., 1997, 23(12), 1275-1278.
93. Tilton, R.G.; Brock, T.A.; Dixon, R.A.F. Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension. Exp. Opin. Investig. Drugs, 2001, 10(7), 1291-1308.
94. Hoeper, M.M.; Schwarze, M.; Ehlerding, S.; Adler-Schuermeyer, A.; Spiekerkoetter, E.; Niedermeyer, J.; Hamm, M.; Fabel, H. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N. Engl. J. Med., 2000, 342(25), 1866-1870.
95. Tanaka, H.; Saito, T.; Kurokawa, K.; Teramoto, S.; Miyazaki, N.; Kaneko, S.; Hashimoto, M.; Abe, S. Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-ketoprostaglandin (PG)F1a. Allergy, 1999, 54(5), 489-494.
96. Tanaka, H.; Igarashi, T.; Saitoh, T.; Teramoto, S.; Miyazaki, N.; Kaneko, S.; Ohmichi, M.; Abe, S. Can urinary eicosanoids be a potential predictive marker of clinical response to thromboxane A2 receptor antagonist in asthmatic patients? Respir. Med., 1999, 93(12), 891-897.
97. Daham, K.; Song, W.L.; Lawson, J.A.; Kupczyk, M.; Gulich, A.; Dahlen, S.E.; FitzGerald, G.A.; Dahlen, B. Effects of celecoxib on major prostaglandins in asthma. Clin. Experimental Allergy, 2011, 41(1), 36-45.
98. Liu, M.C.; Hubbard, W.C.; Proud, D.; Stealey, B.A.; Galli, S.J.; Kagey-Sobotka, A.; Bleecker, E.R.; Lichtenstein, L.M. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am. Rev. Respir. Dis., 1991, 144(1), 51-58.
99. Bochenek, G.; Nizankowska, E.; Gielicz, A.; Swierczynska, M.; Szczeklik, A. Plasma 9a,11b-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma. Thorax, 2004, 59(6), 459-464.
100. Dahlen, S.E.; Kumlin, M. Monitoring mast cell activation by pros-taglandin D2 in vivo. Thorax, 2004, 59(6), 453-455.
101. Urade, Y.; Ujihara, M.; Horiguchi, Y.; Igarashi, M.; Nagata, A.; Ikai, K.; Hayaishi, O. Mast cells contain spleen-type prostaglandin D synthetase. J. Biol. Chem., 1990, 265(1), 371-5.
102. Wu, S.H.; Yin, P.L.; Zhang, Y.M.; Tao, H.X. Reversed changes of lipoxin A4 and leukotrienes in children with asthma in different severity degree. Pediatr. Pulmonol., 2010, 45(4), 333-40.
103. Caballero Balanza, S.; Martorell Aragones, A.; Cerda Mir, J.C.; Belda Ramirez, J.; Navarro Ivanez, R.; Navarro Soriano, A.; Felix Toledo, R.; Escribano Montaner, A. Leukotriene B4 and 8-isoprostane in exhaled breath condensate of children with episodic and persistent asthma. J. Investig. Allergol. Clin. Immunol., 2010, 20(3), 237-243.
104. Rabinovitch, N.; Graber, N.J.; Chinchilli, V.M.; Sorkness, C.A.; Zeiger, R.S.; Strunk, R.C.; Bacharier, L.B.; Martinez, F.D.; Szefler, S.J. Urinary leukotriene E4/exhaled nitric oxide ratio and montelu-kast response in childhood asthma. J. Allergy Clin. Immunol., 2010, 126(3), 545-451 e1-4.
105. Esser, J.; Gehrmann, U.; D'Alexandri, F.L.; Hidalgo-Estevez, A.M.; Wheelock, C.E.; Scheynius, A.; Gabrielsson, S.; Radmark, O. Exosomes from human macrophages and dendritic cells contain enzymes for leukotriene biosynthesis and promote granulocyte migration. J. Allergy Clin. Immunol., 2010, 126(5), 1032-1040.
106. del Giudice, M.M.; Pezzulo, A.; Capristo, C.; Alterio, E.; Cag-giano, S.; de Benedictis, D.; Capristo, A.F. Leukotriene modifiers in the treatment of asthma in children. Ther. Adv. Respir Dis., 2009, 3(5), 245-251.
107. Mehrotra, A.K.; Henderson, W.R. Jr. The role of leukotrienes in airway remodeling. Curr. Mol. Med., 2009, 9(3), 383-391.
108. Hallstrand, T.S.; Henderson, W.R. Jr. An update on the role of leukotrienes in asthma. Curr. Opin. Allergy Clin. Immunol., 2010, 10(1), 60-66.
109. Radmark, O.; Samuelsson, B. Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. Biochem. Biophys. Res. Commun., 2010, 396(1), 105-110.
110. Holgate, S.T.; Peters-Golden, M.; Panettieri, R.A.; Henderson, W.R.J. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J. Allergy Clin. Immunol., 2003, 111(1 Suppl), S18-36.
111. Shimizu, T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol., 2009, 49,123-150.
112. Dixon, R.A.; Diehl, R.E.; Opas, E.; Rands, E.; Vickers, P.J.; Evans, J.F.; Gillard, J.W.; Miller, D.K. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature, 1990, 343(6255), 282-284.
113. Ferguson, A.D.; McKeever, B.M.; Xu, S.; Wisniewski, D.; Miller, D.K.; Yamin, T.T.; Spencer, R.H.; Chu, L.; Ujjainwalla, F.; Cunningham, B.R.; Evans, J.F.; Becker, J.W. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science, 2007, 317(5837), 510-512.
114. Jiang, Y.; Kanaoka, Y.; Feng, C.; Nocka, K.; Rao, S.; Boyce, J.A. Cutting edge: Interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene-induced signaling. J. Immunol., 2006, 177(5), 2755-2759.
115. Thivierge, M.; Doty, M.; Johnson, J.; Stankova, J.; Rola-Pleszczynski, M. IL-5 up-regulates cysteinyl leukotriene 1 receptor expression in HL-60 cells differentiated into eosinophils. J. Immunol., 2000, 165(9), 5221-5226.
116. Vargaftig, B.B.; Singer, M. Leukotrienes mediate murine bron-chopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine inter-leukin-13. Am. J. Respir. Cell Mol. Biol., 2003, 28(4), 410-419.
117. Thivierge, M.; Stankova, J.; Rola-Pleszczynski, M. IL-13 and IL-4 up-regulate cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages. J. Immunol., 2001, 167(5), 2855-2860.
118. Camargo, C.A. Jr.; Smithline, H.A.; Malice, M.P.; Green, S.A.; Reiss, T.F. A randomized controlled trial of intravenous montelukast in acute asthma. Am. J. Respir. Crit. Care Med., 2003, 167(4), 528-533.
119. Silverman, R.A.; Nowak, R.M.; Korenblat, P.E.; Skobeloff, E.; Chen, Y.; Bonuccelli, C.M.; Miller, C.J.; Simonson, S.G. Zafirlu-kast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial. Chest, 2004, 126(5), 1480-1489.
120. Hallstrand, T.S.; Henderson, W.R. Jr. The evolving role of intravenous leukotriene modifiers in acute asthma. J. Allergy Clin. Immunol., 2010, 125(2), 381-382.
121. Lam, B.K.; Penrose, J.F.; Freeman, G.J.; Austen, K.F. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc. Natl. Acad. Sci. USA, 1994, 91(16), 7663-7667.
122. Martinez Molina, D.; Wetterholm, A.; Kohl, A.; McCarthy, A.A.; Niegowski, D.; Ohlson, E.; Hammarberg, T.; Eshaghi, S.; Haegg-strom, J.Z.; Nordlund, P. Structural basis for synthesis of inflammatory mediators by human leukotriene C4 synthase. Nature, 2007, 448(7153), 613-616.
123. Hanna, C.J.; Bach, M.K.; Pare, P.D.; Schellenberg, R.R. Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro. Nature, 1981, 290(5804), 343-344.
124. Kanaoka, Y.; Boyce, J.A. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J. Immunol., 2004, 173(3), 1503-1510.
125. Anderson, M.E.; Allison, R.D.; Meister, A. Interconversion of leukotrienes catalyzed by purified g-glutamyl transpeptidase: concomitant formation of leukotriene D4 and g-glutamyl amino acids. Proc. Natl. Acad. Sci. USA, 1982, 79(4), 1088-1091.
126. Carter, B.Z.; Shi, Z.Z.; Barrios, R.; Lieberman, M.W. gamma-glutamyl leukotrienase, a gamma-glutamyl transpeptidase gene family member, is expressed primarily in spleen. J. Biol. Chem., 1998, 273(43), 28277-28285.
127. Lee, C.W.; Lewis, R.A.; Corey, E.J.; Austen, K.F. Conversion of leukotriene D4 to leukotriene E4 by a dipeptidase released from the specific granule of human polymorphonuclear leucocytes. Immunology, 1983, 48(1), 27-35.
128. Drazen, J.M.; O'Brien, J.; Sparrow, D.; Weiss, S.T.; Martins, M.A.; Israel, E.; Fanta, C.H. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am. Rev. Respir. Dis., 1992, 146(1), 104-108.
129. Kumlin, M. Measurement of leukotrienes in humans. Am. J. Respir. Crit. Care Med., 2000, 161(2 Pt 2), S102-106.
130. Kumlin, M.; Dahlen, B. The challenge procedure influences the extent of allergen-induced urinary excretion of leukotriene E4. Clin. Exp. Allergy, 2000, 30(4), 585-589.
131. Bernard, G.R.; Korley, V.; Chee, P.; Swindell, B.; Ford-Hutchinson, A.W.; Tagari, P. Persistent generation of peptido leu-kotrienes in patients with the adult respiratory distress syndrome. Am. Rev. Respir. Dis., 1991, 144(2), 263-267.
132. Gaber, F.; Daham, K.; Higashi, A.; Higashi, N.; Gulich, A.; Delin, I.; James, A.; Skedinger, M.; Gyllfors, P.; Nord, M.; Dahlen, S.E.; Kumlin, M.; Dahlen, B. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax, 2008, 63(12), 1076-1082.
133. Wenzel, S.E.; Larsen, G.L.; Johnston, K.; Voelkel, N.F.; Westcott, J.Y. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am. Rev. Respir. Dis., 1990, 142(1), 112-119.
134. Deems, R.; Buczynski, M.W.; Bowers-Gentry, R.; Harkewicz, R.; Dennis, E.A. Detection and quantitation of eicosanoids via high performance liquid chromatography-electrospray ionization-mass spectrometry. Methods Enzymol., 2007, 432, 59-82.
135. Evans, J.F.; Dupuis, P.; Ford-Hutchinson, A.W. Purification and characterisation of leukotriene A4 hydrolase from rat neutrophils. Biochim. Biophys Acta, 1985, 840(1), 43-50.
136. De Rose, V.; Trentin, L.; Crivellari, M.T.; Cipriani, A.; Gialdroni Grassi, G.; Pozzi, E.; Folco, G.; Semenzato, G. Release of prosta-glandin E2 and leukotriene B4 by alveolar macrophages from patients with sarcoidosis. Thorax, 1997, 52(1), 76-83.
137. Gaber, F.; Acevedo, F.; Delin, I.; Sundblad, B.M.; Palmberg, L.; Larsson, K.; Kumlin, M.; Dahlen, S.E. Saliva is one likely source of leukotriene B4 in exhaled breath condensate. Eur. Respir. J., 2006, 28(6), 1229-1235.
138. Chiang, N.; Arita, M.; Serhan, C.N. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prosta-glandins Leukot Essent Fatty Acids, 2005, 73(3-4), 163-177.
139. Serhan, C.N.; Samuelsson, B. Lipoxins: a new series of eicosanoids (biosynthesis, stereochemistry, and biological activities). Adv. Exp. Med. Biol., 1988, 229, 1-14.
140. Romano, M. Lipoxin and aspirin-triggered lipoxins. Scientific-WorldJournal, 2010, 10, 1048-1064.
141. Haeggstrom, J.Z.; Rinaldo-Matthis, A.; Wheelock, C.E.; Wetter-holm, A. Advances in eicosanoid research, novel therapeutic implications. Biochem. Biophys Res. Commun., 2010, 396(1), 135-139.
142. Serhan, C.N.; Sheppard, K.A. Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J. Clin. Invest., 1990, 85(3), 772-780.
143. Serhan, C.N. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins, 1997, 53(2), 107-137.
144. Levy, B.D.; De Sanctis, G.T.; Devchand, P.R.; Kim, E.; Ackerman, K.; Schmidt, B.A.; Szczeklik, W.; Drazen, J.M.; Serhan, C.N. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nat. Med., 2002, 8(9), 1018-1023.
145. Bonnans, C.; Vachier, I.; Chavis, C.; Godard, P.; Bousquet, J.; Chanez, P. Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am. J. Respir. Crit. Care Med., 2002, 165(11), 1531-1535.
146. Levy, B.D.; Bonnans, C.; Silverman, E.S.; Palmer, L.J.; Marigowda, G.; Israel, E. Diminished lipoxin biosynthesis in severe asthma. Am. J. Respir. Crit. Care Med., 2005, 172(7), 824-830.
147. Vachier, I.; Bonnans, C.; Chavis, C.; Farce, M.; Godard, P.; Bousquet, J.; Chanez, P. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J. Allergy Clin. Immunol., 2005, 115(1), 55-60.
148. Karp, C.L.; Flick, L.M.; Park, K.W.; Softic, S.; Greer, T.M.; Keled-jian, R.; Yang, R.; Uddin, J.; Guggino, W.B.; Atabani, S.F.; Bel-kaid, Y.; Xu, Y.; Whitsett, J.A.; Accurso, F.J.; Wills-Karp, M.; Petasis, N.A. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol., 2004, 5(4), 388-392.
149. Takai, D.; Nagase, T.; Shimizu, T. New therapeutic key for cystic fibrosis: a role for lipoxins. Nat. Immunol., 2004, 5(4), 357-358.
150. Lasker, J.M.; Chen, W.B.; Wolf, I.; Bloswick, B.P.; Wilson, P.D.; Powell, P.K. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J. Biol. Chem., 2000, 275(6), 4118-4126.
151. Schwartzman, M.L.; da Silva, J.L.; Lin, F.; Nishimura, M.; Abraham, N.G. Cytochrome P450 4A expression and arachidonic acid omega-hydroxylation in the kidney of the spontaneously hypertensive rat. Nephron, 1996, 73(4), 652-663.
152. Powell, W.S.; Rokach, J. Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. Prog. Lipid Res., 2005, 44(2-3), 154-183.
153. Powell, W.S.; Gravel, S.; MacLeod, R.J.; Mills, E.; Hashefi, M. Stimulation of human neutrophils by 5-oxo-6,8,11,14-eicosatetraenoic acid by a mechanism independent of the leukot-riene B4 receptor. J. Biol. Chem., 1993, 268(13), 9280-9286.
154. Morin, C.; Sirois, M.; Echave, V.; Gomes, M.M.; Rousseau, E. Relaxing effects of 5-oxo-ETE on human bronchi involve BKCa channel activation. Prostaglandins Other Lipid Mediat, 2007, 83(4), 311-319.
155. Erlemann, K.R.; Cossette, C.; Gravel, S.; Lesimple, A.; Lee, G.J.; Saha, G.; Rokach, J.; Powell, W.S. Airway epithelial cells synthesize the lipid mediator 5-oxo-ETE in response to oxidative stress. Free Radic. Biol. Med., 2007, 42(5), 654-664.
156. Guilbert, M.; Ferland, C.; Bosse, M.; Flamand, N.; Lavigne, S.; Laviolette, M. 5-Oxo-6,8,11,14-eicosatetraenoic acid induces important eosinophil transmigration through basement membrane components: comparison of normal and asthmatic eosinophils. Am. J. Respir Cell Mol. Biol., 1999, 21(1), 97-104.
157. Muro, S.; Hamid, Q.; Olivenstein, R.; Taha, R.; Rokach, J.; Powell, W.S. 5-oxo-6,8,11,14-eicosatetraenoic acid induces the infiltration of granulocytes into human skin. J. Allergy Clin. Immunol., 2003, 112(4), 768-774.
158. Zijlstra, F.J.; Vincent, J.E.; Mol, W.M.; Hoogsteden, H.C.; Van Hal, P.T.; Jongejan, R.C. Eicosanoid levels in bronchoalveolar lavage fluid of young female smokers and non-smokers. Eur. J. Clin. Invest., 1992, 22(5), 301-306.
159. Kuhn, H.; O'Donnell, V.B. Inflammation and immune regulation by 12/15-lipoxygenases. Prog. Lipid Res., 2006, 45(4), 334-356.
160. Hamberg, M.; Hedqvist, P.; Radegran, K. Identification of 15-hydroxy-5,8,11,13-eicosatetraenoic acid (15-HETE) as a major metabolite of arachidonic acid in human lung. Acta Physiol. Scand, 1980, 110(2), 219-221.
161. Kumlin, M.; Hamberg, M.; Granstrom, E.; Bjorck, T.; Dahlen, B.; Matsuda, H.; Zetterstrom, O.; Dahlen, S.E. 15(S)-hydroxyeico-satetraenoic acid is the major arachidonic acid metabolite in human bronchi: association with airway epithelium. Arch. Biochem. Bio-phys., 1990, 282(2), 254-262.
162. Schnurr, K.; Borchert, A.; Kuhn, H. Inverse regulation of lipid-peroxidizing and hydroperoxyl lipid-reducing enzymes by interleu-kins 4 and 13. FASEB J., 1999, 13(1), 143-54.
163. Liu, C.; Xu, D.; Liu, L.; Schain, F.; Brunnstrom, A.; Bjorkholm, M.; Claesson, H.E.; Sjoberg, J. 15-lipoxygenase-1 induces expression and release of chemokines in cultured human lung epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol., 2009, 297(1), L196-203.
164. Shannon, V.R.; Chanez, P.; Bousquet, J.; Holtzman, M.J. Histo-chemical evidence for induction of arachidonate 15-lipoxygenase in airway disease. Am. Rev. Respir. Dis., 1993, 147(4), 1024-1028.
165. Chu, H.W.; Balzar, S.; Westcott, J.Y.; Trudeau, J.B.; Sun, Y.; Conrad, D.J.; Wenzel, S.E. Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosino-philic phenotype and collagen deposition. Clin. Exp. Allergy, 2002, 32(11), 1558-1565.
166. Denning, G.M.; Stoll, L.L. Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease? Pediatr. Pul-monol., 2006, 41(1), 23-34.
167. Benayoun, L.; Letuve, S.; Druilhe, A.; Boczkowski, J.; Dombret, M.C.; Mechighel, P.; Megret, J.; Leseche, G.; Aubier, M.; Preto-lani, M. Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. Am. J. Respir. Crit. Care Med., 2001, 164(8 Pt 1), 1487-1494.
168. Spears, M.; Donnelly, I.; Jolly, L.; Brannigan, M.; Ito, K.; McSharry, C.; Lafferty, J.; Chaudhuri, R.; Braganza, G.; Bareille, P.; Sweeney, L.; Adcock, I.M.; Barnes, P.J.; Wood, S.; Thomson, N.C. Bronchodilatory effect of the PPAR-gamma agonist rosiglita-zone in smokers with asthma. Clin. Pharmacol. Ther., 2009, 86(1), 49-53.
169. Huynh, M.L.; Malcolm, K.C.; Kotaru, C.; Tilstra, J.A.; Westcott, J.Y.; Fadok, V.A.; Wenzel, S.E. Defective apoptotic cell phagocytosis attenuates prostaglandin E2 and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages. Am. J. Respir. Crit. Care Med., 2005, 172(8), 972-979.
170. Profita, M.; Sala, A.; Riccobono, L.; Pace, E.; Paterno, A.; Zarini, S.; Siena, L.; Mirabella, A.; Bonsignore, G.; Vignola, A.M. 15(S)-HETE modulates LTB4 production and neutrophil chemotaxis in chronic bronchitis. Am. J. Physiol Cell Physiol., 2000, 279(4), C1249-1258.
171. O'Flaherty, J.T.; Kuroki, M.; Nixon, A.B.; Wijkander, J.; Yee, E.; Lee, S.L.; Smitherman, P.K.; Wykle, R.L.; Daniel, L.W. 5-Oxo-eicosanoids and hematopoietic cytokines cooperate in stimulating neutrophil function and the mitogen-activated protein kinase pathway. J. Biol. Chem., 1996, 271(30), 17821-17828.
172. Carroll, M.A.; McGiff, J.C. A new class of lipid mediators: cyto-chrome P450 arachidonate metabolites. Thorax, 2000, 55 (Suppl 2), S13-16.
173. Morin, C.; Sirois, M.; Echave, V.; Gomes, M.M.; Rousseau, E. Functional effects of 20-HETE on human bronchi: hyperpolariza-tion and relaxation due to BKCa channel activation. Am. J. Physiol Lung Cell Mol. Physiol., 2007, 293(4), L1037-1044.
174. Cooper, P.R.; Mesaros, A.C.; Zhang, J.; Christmas, P.; Stark, C.M.; Douaidy, K.; Mittelman, M.A.; Soberman, R.J.; Blair, I.A.; Panet-tieri, R.A. 20-HETE mediates ozone-induced, neutrophil-independent airway hyper-responsiveness in mice. PLoS One, 2010, 5(4), e10235.
175. Jacobs, E.R.; Zeldin, D.C. The lung HETEs (and EETs) up. Am. J. Physiol. Heart Circ. Physiol., 2001, 280(1), H1-H10.
176. Spector, A.A. Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid Res., 2009, 50 (Suppl), S52-56.
177. Spector, A.A.; Fang, X.; Snyder, G.D.; Weintraub, N.L. Epoxyei-cosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res., 2004, 43(1), 55-90.
178. Le Quere, V.; Plee-Gautier, E.; Potin, P.; Madec, S.; Salaun, J.P. Human CYP4F3s are the main catalysts in the oxidation of fatty acid epoxides. J. Lipid Res., 2004, 45(8), 1446-1458.
179. Newman, J.W.; Morisseau, C.; Hammock, B.D. Epoxide hydro-lases: their roles and interactions with lipid metabolism. Prog. Lipid Res., 2005, 44(1), 1-51.
180. Zeldin, D.C.; Kobayashi, J.; Falck, J.R.; Winder, B.S.; Hammock, B.D.; Snapper, J.R.; Capdevila, J.H. Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J. Biol. Chem., 1993, 268(9), 6402-6407.
181. Zeldin, D.C.; Wei, S.; Falck, J.R.; Hammock, B.D.; Snapper, J.R.; Capdevila, J.H. Metabolism of epoxyeicosatrienoic acids by cyto-solic epoxide hydrolase: substrate structural determinants of asymmetric catalysis. Arch. Biochem. Biophys, 1995, 316(1), 443-451.
182. Scarborough, P.E.; Ma, J.; Qu, W.; Zeldin, D.C. P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in ex-trahepatic tissues. Drug Metab. Rev., 1999, 31(1), 205-234.
183. Zeldin, D.C.; Foley, J.; Ma, J.; Boyle, J.E.; Pascual, J.M.; Moomaw, C.R.; Tomer, K.B.; Steenbergen, C.; Wu, S. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Mol. Pharmacol., 1996, 50(5), 1111-1117.
184. Raunio, H.; Hakkola, J.; Hukkanen, J.; Pelkonen, O.; Edwards, R.; Boobis, A.; Anttila, S. Expression of xenobiotic-metabolizing cyto-chrome P450s in human pulmonary tissues. Arch. Toxicol. Suppl., 1998, 20, 465-469.
185. Pascual, J.M.; McKenzie, A.; Yankaskas, J.R.; Falck, J.R.; Zeldin, D.C. Epoxygenase metabolites of arachidonic acid affect electro-physiologic properties of rat tracheal epithelial cells1. J. Pharmacol. Exp. Ther., 1998, 286(2), 772-779.
186. --channel activity by 5,6- and 11,12-EET. Am. J. Physiol., 1998, 275(3 Pt 1), L432-441.
187. Dumoulin, M.; Salvail, D.; Gaudreault, S.B.; Cadieux, A.; Rousseau, E. Epoxyeicosatrienoic acids relax airway smooth muscles and directly activate reconstituted KCa channels. Am. J. Physiol., 1998, 275(3 Pt 1), L423-431.
188. Pokreisz, P.; Fleming, I.; Kiss, L.; Barbosa-Sicard, E.; Fisslthaler, B.; Falck, J.R.; Hammock, B.D.; Kim, I.H.; Szelid, Z.; Vermeersch, P.; Gillijns, H.; Pellens, M.; Grimminger, F.; van Zonneveld, A.J.; Collen, D.; Busse, R.; Janssens, S. Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension, 2006, 47(4), 762-770.
189. Keseru, B.; Barbosa-Sicard, E.; Popp, R.; Fisslthaler, B.; Dietrich, A.; Gudermann, T.; Hammock, B.D.; Falck, J.R.; Weissmann, N.; Busse, R.; Fleming, I. Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. FASEB J., 2008, 22(12), 4306-4315.
190. Liu, Y.; Zhang, Y.; Schmelzer, K.; Lee, T.S.; Fang, X.; Zhu, Y.; Spector, A.A.; Gill, S.; Morisseau, C.; Hammock, B.D.; Shyy, J.Y. The antiinflammatory effect of laminar flow: the role of PPAR-gamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl. Acad. Sci. USA, 2005, 102(46), 16747-16752.
191. Campbell, W.B. New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. Trends Pharmacol. Sci., 2000, 21(4), 125-127.
192. Zeldin, D.C.; Liao, J.K. Reply: cytochrome P450-derived eicosa-noids and the vascular wall. Trends Pharmacol. Sci., 2000, 21(4), 127-128.
193. Node, K.; Huo, Y.; Ruan, X.; Yang, B.; Spiecker, M.; Ley, K.; Zeldin, D.C.; Liao, J.K. Anti-inflammatory properties of cyto-chrome P450 epoxygenase-derived eicosanoids. Science, 1999, 285(5431), 1276-1279.
194. Smith, K.R.; Pinkerton, K.E.; Watanabe, T.; Pedersen, T.L.; Ma, S.J.; Hammock, B.D. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc. Natl. Acad. Sci. USA, 2005, 102(6), 2186-2191.
195. Kiss, L.; Schutte, H.; Mayer, K.; Grimm, H.; Padberg, W.; Seeger, W.; Grimminger, F. Synthesis of arachidonic acid-derived lipoxy-genase and cytochrome P450 products in the intact human lung vasculature. Am. J. Respir. Crit. Care Med., 2000, 161(6), 1917-1923.
196. Kiss, L.; Schutte, H.; Padberg, W.; Weissmann, N.; Mayer, K.; Gessler, T.; Voswinckel, R.; Seeger, W.; Grimminger, F. Epoxyei-cosatrienoates are the dominant eicosanoids in human lungs upon microbial challenge. Eur. Respir. J., 2010, 36(5), 1088-1098.
197. Kiss, L.; Roder, Y.; Bier, J.; Weissmann, N.; Seeger, W.; Grim-minger, F. Direct eicosanoid profiling of the hypoxic lung by comprehensive analysis via capillary liquid chromatography with dual online photodiode-array and tandem mass-spectrometric detection. Anal. Bioanal. Chem., 2008, 390(2), 697-714.
198. Zeldin, D.C.; Plitman, J.D.; Kobayashi, J.; Miller, R.F.; Snapper, J.R.; Falck, J.R.; Szarek, J.L.; Philpot, R.M.; Capdevila, J.H. The rabbit pulmonary cytochrome P450 arachidonic acid metabolic pathway: characterization and significance. J. Clin. Invest., 1995, 95(5), 2150-2160.
199. Jubiz, W.; Radmark, O.; Lindgren, J.A.; Malmsten, C.; Samuels-son, B. Novel leukotrienes: products formed by initial oxygenation of arachidonic acid at C-15. Biochem. Biophys Res. Commun., 1981, 99(3), 976-986.
200. Maas, R.L.; Brash, A.R. Evidence for a lipoxygenase mechanism in the biosynthesis of epoxide and dihydroxy leukotrienes from 15(S)-hydroperoxyicosatetraenoic acid by human platelets and porcine leukocytes. Proc. Natl. Acad. Sci. USA, 1983, 80(10), 2884-2888.
201. Feltenmark, S.; Gautam, N.; Brunnstrom, A.; Griffiths, W.; Back-man, L.; Edenius, C.; Lindbom, L.; Bjorkholm, M.; Claesson, H.E. Eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in human eosinophils and mast cells. Proc. Natl. Acad. Sci. USA, 2008, 105(2), 680-685.
202. Ono, E.; Mita, H.; Taniguchi, M.; Higashi, N.; Hasegawa, M.; Miyazaki, E.; Kumamoto, T.; Akiyama, K. Concentration of 14,15-leukotriene C4 (eoxin C4) in bronchoalveolar lavage fluid. Clin. Exp. Allergy, 2009, 39(9), 1348-1352.
203. Drazen, J.M.; Lewis, R.A.; Austen, K.F.; Toda, M.; Brion, F.; Marfat, A.; Corey, E.J. Contractile activities of structural analogs of leukotrienes C and D: necessity of a hydrophobic region. Proc. Natl. Acad. Sci. USA, 1981, 78(5), 3195-3198.
204. Sachs-Olsen, C.; Sanak, M.; Lang, A.M.; Gielicz, A.; Mowinckel, P.; Lodrup Carlsen, K.C.; Carlsen, K.H.; Szczeklik, A. Eoxins: a new inflammatory pathway in childhood asthma. J. Allergy Clin. Immunol., 2010, 126(4), 859-867 e9.
205. Morrow, J.D.; Minton, T.A.; Roberts, L.J. The F2-isoprostane, 8-epi-prostaglandin F2a, a potent agonist of the vascular throm-boxane/endoperoxide receptor, is a platelet throm-boxane/endoperoxide receptor antagonist. Prostaglandins, 1992, 44(2), 155-163.
206. Milne, G.L.; Yin, H.; Morrow, J.D. Human biochemistry of the isoprostane pathway. J. Biol. Chem., 2008, 283(23), 15533-15537.
207. Roberts, L.J. 2nd; Milne, G.L. Isoprostanes. J. Lipid Res., 2009, 50 (Suppl), S219-223.
208. Montuschi, P.; Corradi, M.; Ciabattoni, G.; Nightingale, J.; Khari-tonov, S.A.; Barnes, P.J. Increased 8-isoprostane, a marker of oxi-dative stress, in exhaled condensate of asthma patients. Am. J. Respir. Crit. Care Med., 1999, 160(1), 216-220.
209. Dworski, R.; Murray, J.J.; Roberts, L.J.; Oates, J.A.; Morrow, J.D.; Fisher, L.; Sheller, J.R. Allergen-induced synthesis of F2-isoprostanes in atopic asthmatics - Evidence for oxidant stress. Am. J. Respir. Crit. Care Med., 1999, 160(6), 1947-1951.
210. Montuschi, P.; Ciabattoni, G.; Paredi, P.; Pantelidis, P.; du Bois, R.M.; Kharitonov, S.A.; Barnes, P.J. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am. J. Respir. Crit. Care Med., 1998, 158(5), 1524-1527.
211. Janssen, L.J. Isoprostanes and lung vascular pathology. Am. J. Respir. Cell Mol. Biol., 2008, 39(4), 383-389.
212. Janssen, L.J. Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am. J. Physiol. Lung Cell Mol. Physiol., 2001, 280(6), L1067-L1082.
213. Kunapuli, P.; Lawson, J.A.; Rokach, J.; FitzGerald, G.A. Functional characterization of the ocular prostaglandin F2a (PGF2a) receptor - Activation by the isoprostane, 12-iso-PGF2a. J. Biol. Chem., 1997, 272(43), 27147-27154.
214. Oga, T.; Matsuoka, T.; Yao, C.C.; Nonomura, K.; Kitaoka, S.; Sakata, D.; Kita, Y.; Tanizawa, K.; Taguchi, Y.; Chin, K.; Mishima, M.; Shimizu, T.; Narumiya, S. Prostaglandin F2a receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nat. Med., 2009, 15(12), 1426-U12.
215. Jahn, U.; Galano, J.M.; Durand, T. Beyond prostaglandins - Chemistry and biology of cyclic oxygenated metabolites formed by free-radical pathways from polyunsaturated fatty acids. Angew Chem. Int. Ed., 2008, 47(32), 5894-5955.
216. Cracowski, J.L.; Cracowski, C.; Bessard, G.; Pepin, J.L.; Bessard, J.; Schwebel, C.; Stanke-Labesque, F.; Pison, C. Increased lipid peroxidation in patients with pulmonary hypertension. Am. J. Respir. Crit. Care Med., 2001, 164(6), 1038-1042.
217. Wood, L.G.; Gibson, P.G.; Garg, M.L. Biomarkers of lipid peroxi-dation, airway inflammation and asthma. Eur. Respir J., 2003, 21(1), 177-186.
218. Morrow, J.D.; Hill, K.E.; Burk, R.F.; Nammour, T.M.; Badr, K.F.; Roberts, L.J. 2nd, A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA, 1990, 87(23), 9383-7.
219. Montuschi, P.; Collins, J.V.; Ciabattoni, G.; Lazzeri, N.; Corradi, M.; Kharitonov, S.A.; Barnes, P.J. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med., 2000, 162(3), 1175-1177.
220. Kinnula, V.L.; Ilumets, H.; Myllarniemi, M.; Sovijarvi, A.; Rytila, P. 8-Isoprostane as a marker of oxidative stress in nonsymptomatic cigarette smokers and COPD. Eur. Respir. J., 2007, 29(1), 51-55.
221. Psathakis, K.; Papatheodorou, G.; Plataki, M.; Panagou, P.; Lou-kides, S.; Siafakas, N.M.; Bouros, D. 8-isoprostane, a marker of oxidative stress, is increased in the expired breath condensate of patients with pulmonary sarcoidosis. Chest, 2004, 125(3), 1005-1011.
222. Montuschi, P.; Kharitonov, S.A.; Ciabattoni, G.; Corradi, M.; van Rensen, L.; Geddes, D.M.; Hodson, M.E.; Barnes, P.J. Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stress in cystic fibrosis. Thorax, 2000, 55(3), 205-209.
223. Lucidi, V.; Ciabattoni, G.; Bella, S.; Barnes, P.J.; Montuschi, P. Exhaled 8-isoprostane and prostaglandin E2 in patients with stable and unstable cystic fibrosis. Free Radic. Biol. Med., 2008, 45(6), 913-919.
224. Collins, C.E.; Quaggiotto, P.; Wood, L.; O'Loughlin, E.V.; Henry, R.L.; Garg, M.L. Elevated plasma levels of F2 alpha isoprostane in cystic fibrosis. Lipids, 1999, 34(6), 551-556.
225. Wood, L.G.; Fitzgerald, D.A.; Gibson, P.G.; Cooper, D.M.; Collins, C.E.; Garg, M.L. Oxidative stress in cystic fibrosis: dietary and metabolic factors. J. Am. Coll Nutr., 2001, 20(2 Suppl), 157-165.
226. Samitas, K.; Chorianopoulos, D.; Vittorakis, S.; Zervas, E.; Economidou, E.; Papatheodorou, G.; Loukides, S.; Gaga, M. Exhaled cysteinyl-leukotrienes and 8-isoprostane in patients with asthma and their relation to clinical severity. Respir Med., 2009, 103(5), 750-756.
227. Shahid, S.K.; Kharitonov, S.A.; Wilson, N.M.; Bush, A.; Barnes, P.J. Exhaled 8-isoprostane in childhood asthma. Respir. Res., 2005, 6, 79.
228. Mondino, C.; Ciabattoni, G.; Koch, P.; Pistelli, R.; Trove, A.; Barnes, P.J.; Montuschi, P. Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. J. Allergy Clin. Immunol., 2004, 114(4), 761-767.
229. Baraldi, E.; Carraro, S.; Alinovi, R.; Pesci, A.; Ghiro, L.; Bodini, A.; Piacentini, G.; Zacchello, F.; Zanconato, S. Cysteinyl leukot-rienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations. Thorax, 2003, 58(6), 505-509.
230. Cairns, C.B. Acute asthma exacerbations: phenotypes and management. Clin. Chest Med., 2006, 27(1), 99-108, vi-vii.
231. McFadden, E.R. Jr. Acute severe asthma. Am. J. Respir. Crit. Care Med., 2003, 168(7), 740-759.
232. Barreto, M.; Villa, M.P.; Olita, C.; Martella, S.; Ciabattoni, G.; Montuschi, P. 8-Isoprostane in exhaled breath condensate and exercise-induced bronchoconstriction in asthmatic children and adolescents. Chest, 2009, 135(1), 66-73.
233. Dworski, R.; Roberts, L.J.; Murray, J.J.; Morrow, J.D.; Hartert, T.V.; Sheller, J.R. Assessment of oxidant stress in allergic asthma by measurement of the major urinary metabolite of F2-isoprostane, 15-F2t-IsoP (8-iso-PGF2a). Clin. Exp. Allergy, 2001, 31(3), 387-390.
234. Das, U.N. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol. J., 2006, 1(4), 420-439.
235. Cho, H.P.; Nakamura, M.; Clarke, S.D. Cloning, expression, and fatty acid regulation of the human delta-5 desaturase. J. Biol. Chem., 1999, 274(52), 37335-37339.
236. Cho, H.P.; Nakamura, M.T.; Clarke, S.D. Cloning, expression, and nutritional regulation of the mammalian Delta-6 desaturase. J. Biol. Chem., 1999, 274(1), 471-477.
237. Simopoulos, A.P. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp. Biol. Med. (Maywood), 2008, 233(6), 674-688.
238. Oliw, E.H.; Brodowsky, I.D.; Hornsten, L.; Hamberg, M. Bis-allylic hydroxylation of polyunsaturated fatty acids by hepatic monooxygenases and its relation to the enzymatic and nonenzy-matic formation of conjugated hydroxy fatty acids. Arch. Biochem. Biophys, 1993, 300(1), 434-439.
239. Oliw, E.H. Analysis of 1,2-diols of linoleic, alpha-linolenic and arachidonic acid by gas chromatography--mass spectrometry using cyclic alkyl boronic esters. J. Chromatogr., 1983, 275(2), 245-259.
240. Moghaddam, M.F.; Grant, D.F.; Cheek, J.M.; Greene, J.F.; Williamson, K.C.; Hammock, B.D. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat. Med., 1997, 3(5), 562-566.
241. Ziboh, V.A.; Miller, C.C.; Cho, Y. Significance of lipoxygenase-derived monohydroxy fatty acids in cutaneous biology. Prosta-glandins Other Lipid Mediat, 2000, 63(1-2), 3-13.
242. Ozawa, T.; Hayakawa, M.; Takamura, T.; Sugiyama, S.; Suzuki, K.; Iwata, M.; Taki, F.; Tomita, T. Biosynthesis of leukotoxin, 9,10-epoxy-12 octadecenoate, by leukocytes in lung lavages of rat after exposure to hyperoxia. Biochem. Biophys Res. Commun., 1986, 134(3), 1071-1078.
243. Ozawa, T.; Sugiyama, S.; Hayakawa, M.; Satake, T.; Taki, F.; Iwata, M.; Taki, K. Existence of leukotoxin 9,10-epoxy-12-octadecenoate in lung lavages from rats breathing pure oxygen and from patients with the adult respiratory distress syndrome. Am. Rev. Respir. Dis., 1988, 137(3), 535-540.
244. Totani, Y.; Saito, Y.; Ishizaki, T.; Sasaki, F.; Ameshima, S.; Mi-yamori, I. Leukotoxin and its diol induce neutrophil chemotaxis through signal transduction different from that of fMLP. Eur. Respir. J., 2000, 15(1), 75-79.
245. Sevanian, A.; Mead, J.F.; Stein, R.A. Epoxides as products of lipid autoxidation in rat lungs. Lipids, 1979, 14(7), 634-643.
246. Nagy, L.; Tontonoz, P.; Alvarez, J.G.; Chen, H.; Evans, R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARg. Cell, 1998, 93(2), 229-40.
247. Hsi, L.C.; Wilson, L.; Nixon, J.; Eling, T.E. 15-lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor gamma via the MAPK signaling pathway. J. Biol. Chem., 2001, 276(37), 34545-34552.
248. Yuan, H.; Li, M.Y.; Ma, L.T.; Hsin, M.K.; Mok, T.S.; Underwood, M.J.; Chen, G.G. 15-Lipoxygenases and its metabolites 15(S)-HETE and 13(S)-HODE in the development of non-small cell lung cancer. Thorax, 2010, 65(4), 321-6.
249. Altmann, R.; Hausmann, M.; Spottl, T.; Gruber, M.; Bull, A.W.; Menzel, K.; Vogl, D.; Herfarth, H.; Scholmerich, J.; Falk, W.; Ro-gler, G. 13-Oxo-ODE is an endogenous ligand for PPARgamma in human colonic epithelial cells. Biochem. Pharmacol., 2007, 74(4), 612-22.
250. Itoh, T.; Fairall, L.; Amin, K.; Inaba, Y.; Szanto, A.; Balint, B.L.; Nagy, L.; Yamamoto, K.; Schwabe, J.W. Structural basis for the activation of PPARg by oxidized fatty acids. Nat. Struct. Mol. Biol., 2008, 15(9), 924-931.
251. Lundström, S.L.; Levänen, B.; Nording, M.; Klepczynska-Nyström, A.; Sköld, M.; Haeggström, J.Z.; Grunewald, J.; Svarten-gren, M.; Hammock, B.D.; Larsson, B.-M.; Eklund, A.; Wheelock, C.E.; Wheelock, Å.M. Asthmatics exhibit altered oxylipin profiles compared to healthy individuals after subway air exposure. [Unpublished Data].
252. Serhan, C.N.; Chiang, N.; Van Dyke, T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat.Rev. Immunol., 2008, 8(5), 349-361.
253. Kohli, P.; Levy, B.D. Resolvins and protectins: mediating solutions to inflammation. Br. J. Pharmacol., 2009, 158(4), 960-971.
254. Wall, R.; Ross, R.P.; Fitzgerald, G.F.; Stanton, C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr. Rev., 2010, 68(5), 280-289.
255. Bannenberg, G.; Serhan, C.N. Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim. Biophys. Acta., 2010, 1801(12), 1260-1273.
256. Carlo, T.; Levy, B.D. Molecular circuits of resolution in airway inflammation. ScientificWorldJournal, 2010, 10, 1386-1399.
257. Bannenberg, G.L. Therapeutic applicability of anti-inflammatory and proresolving polyunsaturated fatty acid-derived lipid mediators. ScientificWorldJournal, 2010, 10, 676-712.
258. Norling, L.V.; Serhan, C.N. Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination. J. Intern. Med., 2010, 268(1), 15-24.
259. Calder, P.C. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr., 2006, 83(6 Suppl), 1505S-1519S.
260. Harris, W.S.; Miller, M.; Tighe, A.P.; Davidson, M.H.; Schaefer, E.J. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis, 2008, 197(1), 12-24.
261. Cawood, A.L.; Ding, R.; Napper, F.L.; Young, R.H.; Williams, J.A.; Ward, M.J.; Gudmundsen, O.; Vige, R.; Payne, S.P.; Ye, S.; Shearman, C.P.; Gallagher, P.J.; Grimble, R.F.; Calder, P.C. Eicos-apentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis, 2010, 212(1), 252-259.
262. Saravanan, P.; Davidson, N.C.; Schmidt, E.B.; Calder, P.C. Cardiovascular effects of marine omega-3 fatty acids. Lancet, 2010, 376(9740), 540-550.
263. Stear, S.J.; Castell, L.M.; Burke, L.M.; Jeacocke, N.; Ekblom, B.; Shing, C.; Calder, P.C.; Lewis, N. A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance--part 10. Br. J. Sports Med., 2010, 44(9), 688-690.
264. Mickleborough, T.D. Dietary omega-3 polyunsaturated fatty acid supplementation and airway hyperresponsiveness in asthma. J. Asthma, 2005, 42(5), 305-314.
265. London, B.; Albert, C.; Anderson, M.E.; Giles, W.R.; Van Wagoner, D.R.; Balk, E.; Billman, G.E.; Chung, M.; Lands, W.; Leaf, A.; McAnulty, J.; Martens, J.R.; Costello, R.B.; Lathrop, D.A. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhyth-mogenesis Workshop. Circulation, 2007, 116(10), e320-335.
266. Shearer, G.C.; Harris, W.S.; Pedersen, T.L.; Newman, J.W. Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J. Lipid Res., 2010, 51(8), 2074-2081.
267. Serhan, C.N.; Clish, C.B.; Brannon, J.; Colgan, S.P.; Chiang, N.; Gronert, K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and tran-scellular processing. J. Exp. Med., 2000, 192(8), 1197-1204.
268. Tjonahen, E.; Oh, S.F.; Siegelman, J.; Elangovan, S.; Percarpio, K.B.; Hong, S.; Arita, M.; Serhan, C.N. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol., 2006, 13(11), 1193-1202.
269. Serhan, C.N.; Hong, S.; Gronert, K.; Colgan, S.P.; Devchand, P.R.; Mirick, G.; Moussignac, R.L. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro inflammation signals. J. Exp. Med., 2002, 196(8), 1025-1037.
270. Campbell, E.L.; Louis, N.A.; Tomassetti, S.E.; Canny, G.O.; Arita, M.; Serhan, C.N.; Colgan, S.P. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J., 2007, 21(12), 3162-3170.
271. Arita, M.; Ohira, T.; Sun, Y.P.; Elangovan, S.; Chiang, N.; Serhan, C.N. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol., 2007, 178(6), 3912-3917.
272. Arita, M.; Bianchini, F.; Aliberti, J.; Sher, A.; Chiang, N.; Hong, S.; Yang, R.; Petasis, N.A.; Serhan, C.N. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med., 2005, 201(5), 713-722.
273. Haworth, O.; Cernadas, M.; Yang, R.; Serhan, C.N.; Levy, B.D. Resolvin E1 regulates interleukin 23, interferon-g and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat. Immunol., 2008, 9(8), 873-879.
274. Sun, Y.P.; Oh, S.F.; Uddin, J.; Yang, R.; Gotlinger, K.; Campbell, E.; Colgan, S.P.; Petasis, N.A.; Serhan, C.N. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J. Biol. Chem., 2007, 282(13), 9323-9334.
275. Serhan, C.N.; Gotlinger, K.; Hong, S.; Lu, Y.; Siegelman, J.; Baer, T.; Yang, R.; Colgan, S.P.; Petasis, N.A. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J. Immunol., 2006, 176(3), 1848-1859.
276. Hong, S.; Lu, Y.; Yang, R.; Gotlinger, K.H.; Petasis, N.A.; Serhan, C.N. Resolvin D1, protectin D1, and related docosahexaenoic acid-derived products: Analysis via electrospray/low energy tandem mass spectrometry based on spectra and fragmentation mechanisms. J. Am. Soc. Mass Spectrom., 2007, 18(1), 128-144.
277. Levy, B.D.; Kohli, P.; Gotlinger, K.; Haworth, O.; Hong, S.; Ka-zani, S.; Israel, E.; Haley, K.J.; Serhan, C.N. Protectin D1 is generated in asthma and dampens airway inflammation and hyperrespon-siveness. J. Immunol., 2007, 178(1), 496-502.
278. Ariel, A.; Li, P.L.; Wang, W.; Tang, W.X.; Fredman, G.; Hong, S.; Gotlinger, K.H.; Serhan, C.N. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J. Biol. Chem., 2005, 280(52), 43079-86.
279. Serhan, C.N.; Yang, R.; Martinod, K.; Kasuga, K.; Pillai, P.S.; Porter, T.F.; Oh, S.F.; Spite, M. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med., 2009, 206(1), 15-23.
280. Kulkarni, P.S.; Kaufman, P.L.; Srinivasan, B.D. Eicosapentaenoic acid metabolism in cynomolgus and rhesus conjunctiva and eyelid. J. Ocul. Pharmacol., 1987, 3(4), 349-56.
281. Miller, C.C.; Ziboh, V.A.; Wong, T.; Fletcher, M.P. Dietary supplementation with oils rich in (n-3) and (n-6) fatty acids influences in vivo levels of epidermal lipoxygenase products in guinea pigs. J. Nutr., 1990, 120(1), 36-44.
282. Lundstrom, S.L.; Yang, J.; Haeggström, J.Z.; Hammock, B.D.; Grunewald, J.; Eklund, A.; Nord, M.; Wheelock, Å.M.; Wheelock, C.E. Allergic asthmatics exhibit altered responses in oxylipin profiles compared to healthy and asthmatic controls following allergen provocation. [Unpublished Data].
283. Freedman, S.D.; Blanco, P.G.; Zaman, M.M.; Shea, J.C.; Ollero, M.; Hopper, I.K.; Weed, D.A.; Gelrud, A.; Regan, M.M.; Laposata, M.; Alvarez, J.G.; O'Sullivan, B.P. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med., 2004, 350(6), 560-569.
284. McKeever, T.M.; Britton, J. Diet and asthma. Am. J. Respir. Crit. Care Med., 2004, 170(7), 725-729.
285. Simopoulos, A.P. Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their role in the determination of nutritional requirements and chronic disease risk. Exp. Biol. Med. (Maywood), 2010, 235(7), 785-795.
286. Romieu, I.; Trenga, C. Diet and obstructive lung diseases. Epidemiol. Rev., 2001, 23(2), 268-287.
287. Nagakura, T.; Matsuda, S.; Shichijyo, K.; Sugimoto, H.; Hata, K. Dietary supplementation with fish oil rich in omega-3 polyunsatu-rated fatty acids in children with bronchial asthma. Eur. Respir. J., 2000, 16(5), 861-865.
288. Farrell, P.M.; Mischler, E.H.; Engle, M.J.; Brown, D.J.; Lau, S.M. Fatty acid abnormalities in cystic fibrosis. Pediatr. Res., 1985, 19(1), 104-109.
289. Gaskin, K.; Gurwitz, D.; Durie, P.; Corey, M.; Levison, H.; Forstner, G. Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption. J. Pediatr., 1982, 100(6), 857-862.
290. Mimoun, M.; Coste, T.C.; Lebacq, J.; Lebecque, P.; Wallemacq, P.; Leal, T.; Armand, M. Increased tissue arachidonic acid and reduced linoleic acid in a mouse model of cystic fibrosis are reversed by supplemental glycerophospholipids enriched in docosahexaenoic acid. J. Nutr., 2009, 139(12), 2358-2364.
291. Payet, M.; Esmail, M.H.; Polichetti, E.; Le Brun, G.; Adjemout, L.; Donnarel, G.; Portugal, H.; Pieroni, G. Docosahexaenoic acid-enriched egg consumption induces accretion of arachidonic acid in erythrocytes of elderly patients. Br. J. Nutr., 2004, 91(5), 789-796.
292. De Vizia, B.; Raia, V.; Spano, C.; Pavlidis, C.; Coruzzo, A.; Alessio, M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fi-brosis. JPEN J. Parenter Enteral Nutr., 2003, 27(1), 52-57.
293. Lloyd-Still, J.D.; Powers, C.A.; Hoffman, D.R.; Boyd-Trull, K.; Lester, L.A.; Benisek, D.C.; Arterburn, L.M. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition, 2006, 22(1), 36-46.
294. Katz, D.P.; Manner, T.; Furst, P.; Askanazi, J. The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis. Nutrition, 1996, 12(5), 334-339.
295. Durieu, I.; Vericel, E.; Guichardant, D.; Roth, H.; Steghens, J.P.; Drai, J.; Josserand, R.N.; Fontaine, E.; Lagarde, M.; Bellon, G. Fatty acids platelets and oxidative markers following intravenous n-3 fatty acids administration in cystic fibrosis: An open pilot observational study. J. Cyst Fibros., 2007, 6(5), 320-326.
296. Strandvik, B. Fatty acid metabolism in cystic fibrosis. Prostagland-ins Leukot Essent Fatty Acids, 2010, 83(3), 121-129.
297. Coste, T.C.; Armand, M.; Lebacq, J.; Lebecque, P.; Wallemacq, P.; Leal, T. An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clin. Biochem., 2007, 40(8), 511-520.
298. Gadek, J.E.; DeMichele, S.J.; Karlstad, M.D.; Pacht, E.R.; Dona-hoe, M.; Albertson, T.E.; Van Hoozen, C.; Wennberg, A.K.; Nelson, J.L.; Noursalehi, M. Effect of enteral feeding with eicosapen-taenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. Crit. Care Med., 1999, 27(8), 1409-20.
299. Pacht, E.R.; DeMichele, S.J.; Nelson, J.L.; Hart, J.; Wennberg, A.K.; Gadek, J.E. Enteral nutrition with eicosapentaenoic acid, g-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome. Crit. Care Med., 2003, 31(2), 491-500.
300. Arm, J.P.; Horton, C.E.; Mencia-Huerta, J.M.; House, F.; Eiser, N.M.; Clark, T.J.; Spur, B.W.; Lee, T.H. Effect of dietary supplementation with fish oil lipids on mild asthma. Thorax, 1988, 43(2), 84-92.
301. Arm, J.P.; Horton, C.E.; Spur, B.W.; Mencia-Huerta, J.M.; Lee, T.H. The effects of dietary supplementation with fish oil lipids on the airways response to inhaled allergen in bronchial asthma. Am. Rev. Respir. Dis., 1989, 139(6), 1395-1400.
302. Arm, J.P.; Lee, T.H. The use of fish oil in bronchial asthma. Allergy Proc., 1989, 10(3), 185-187.
303. Arm, J.P.; Thien, F.C.; Lee, T.H. Leukotrienes, fish-oil, and asthma. Allergy Proc., 1994, 15(3), 129-134.
304. Fogarty, A.; Britton, J. The role of diet in the aetiology of asthma. Clin. Exp. Allergy, 2000, 30(5), 615-627.
305. Mickleborough, T.D.; Murray, R.L.; Ionescu, A.A.; Lindley, M.R. Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes. Am. J. Respir. Crit. Care Med., 2003, 168(10), 1181-1189.
306. Mickleborough, T.D.; Lindley, M.R.; Ionescu, A.A.; Fly, A.D. Protective effect of fish oil supplementation on exercise-induced bronchoconstriction in asthma. Chest, 2006, 129(1), 39-49.
307. McKeever, T.M.; Lewis, S.A.; Cassano, P.A.; Ocke, M.; Burney, P.; Britton, J.; Smit, H.A. The relation between dietary intake of individual fatty acids, FEV1 and respiratory disease in Dutch adults. Thorax, 2008, 63(3), 208-214.
308. Broadfield, E.C.; McKeever, T.M.; Whitehurst, A.; Lewis, S.A.; Lawson, N.; Britton, J.; Fogarty, A. A case-control study of dietary and erythrocyte membrane fatty acids in asthma. Clin. Exp. Allergy, 2004, 34(8), 1232-1236.
309. Yang, J.; Schmelzer, K.; Georgi, K.; Hammock, B.D. Quantitative profiling method for oxylipin metabolome by liquid chromatogra-phy electrospray ionization tandem mass spectrometry. Anal. Chem., 2009, 81(19), 8085-8093.
310. Lundstrom, S.L.; D'Alexandri, F.L.; Nithipatikom, K.; Haeggstrom, J.Z.; Wheelock, A.M.; Wheelock, C.E. HPLC/MS/MS-based approaches for detection and quantification of eicosanoids. Methods Mol. Biol., 2009, 579, 161-187.
311. Blaho, V.A.; Buczynski, M.W.; Brown, C.R.; Dennis, E.A. Lipi-domic analysis of dynamic eicosanoid responses during the induction and resolution of Lyme arthritis. J. Biol. Chem., 2009, 284(32), 21599-21612.
312. Masoodi, M.; Eiden, M.; Koulman, A.; Spaner, D.; Volmer, D.A. Comprehensive Lipidomics Analysis of Bioactive Lipids in Complex Regulatory Networks. Anal. Chem., 2010, 82(19), 8176-8185.
313. Kita, Y.; Takahashi, T.; Uozumi, N.; Shimizu, T. A multiplex quantitation method for eicosanoids and platelet-activating factor using column-switching reversed-phase liquid chromatography-tandem mass spectrometry. Anal. Biochem., 2005, 342(1), 134-143.
314. Schmelzer, K.R.; Inceoglu, B.; Kubala, L.; Kim, I.H.; Jinks, S.L.; Eiserich, J.P.; Hammock, B.D. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. USA, 2006, 103(37), 13646-13651.
315. Masoodi, M.; Nicolaou, A. Lipidomic analysis of twenty-seven prostanoids and isoprostanes by liquid chromatogra-phy/electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom., 2006, 20(20), 3023-3029.
316. Kempen, E.C.; Yang, P.; Felix, E.; Madden, T.; Newman, R.A. Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatogra-phy/electrospray ionization tandem mass spectrometry. Anal. Bio-chem., 2001, 297(2), 183-190.
317. Kishi, N.; Mano, N.; Asakawa, N. Direct injection method for quantitation of endogenous leukotriene E4 in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry with a column-switching technique. Anal. Sci., 2001, 17(6), 709-713.
318. Zhang, J.H.; Pearson, T.; Matharoo-Ball, B.; Ortori, C.A.; Warren, A.Y.; Khan, R.; Barrett, D.A. Quantitative profiling of epoxyei-cosatrienoic, hydroxyeicosatetraenoic, and dihydroxyeicosatet-raenoic acids in human intrauterine tissues using liquid chromatog-raphy/electrospray ionization tandem mass spectrometry. Anal. Biochem., 2007, 365(1), 40-51.
319. Saunders, R.D.; Horrocks, L.A. Simultaneous extraction and preparation for high-performance liquid chromatography of prostagland-ins and phospholipids. Anal. Biochem., 1984, 143(1), 71-75.
320. Kita, Y.; Takahashi, T.; Uozumi, N.; Nallan, L.; Gelb, M.H.; Shi-mizu, T. Pathway-oriented profiling of lipid mediators in macro-phages. Biochem. Biophys Res. Commun., 2005, 330(3), 898-906.
321. Serhan, C.N.; Jain, A.; Marleau, S.; Clish, C.; Kantarci, A.; Behbe-hani, B.; Colgan, S.P.; Stahl, G.L.; Merched, A.; Petasis, N.A.; Chan, L.; Van Dyke, T.E. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol., 2003, 171(12), 6856-6865.
322. Buczynski, M.W.; Svensson, C.I.; Dumlao, D.S.; Fitzsimmons, B.L.; Shim, J.H.; Scherbart, T.J.; Jacobsen, F.E.; Hua, X.Y.; Yaksh, T.L.; Dennis, E.A. Inflammatory hyperalgesia induces essential bioactive lipid production in the spinal cord. J. Neurochem., 2010, 114(4), 981-993.
323. van Erk, M.J.; Wopereis, S.; Rubingh, C.; van Vliet, T.; Verheij, E.; Cnubben, N.H.; Pedersen, T.L.; Newman, J.W.; Smilde, A.K.; van der Greef, J.; Hendriks, H.F.; van Ommen, B. Insight in modulation of inflammation in response to diclofenac intervention: a human intervention study. BMC Med. Genom., 2010, 3, 5.
324. Serhan, C.N. Mediator lipidomics. Prostaglandins Other Lipid Mediat., 2005, 77(1-4), 4-14.
325. Collins, C.E.; Quaggiotto, P.; Wood, L.; O'Loughlin, E.V.; Henry, R.L.; Garg, M.L. Elevated plasma levels of F2a isoprostane in cystic fibrosis. Lipids, 1999, 34(6), 551-556.
326. Piotrowski, W.J.; Antczak, A.; Marczak, J.; Nawrocka, A.; Kurma-nowska, Z.; Gorski, P. Eicosanoids in exhaled breath condensate and BAL fluid of patients with sarcoidosis. Chest, 2007, 132(2), 589-596.
327. Keatings, V.M.; Evans, D.J.; O'Connor, B.J.; Barnes, P.J. Cellular profiles in asthmatic airways: a comparison of induced sputum, bronchial washings, and bronchoalveolar lavage fluid. Thorax, 1997, i(4), 372-374.
328. Rutgers, S.R.; Timens, W.; Kaufmann, H.F.; van der Mark, T.W.; Koeter, G.H.; Postma, D.S. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur. Respir J., 2000, 15(1), 109-15.
329. D'Ippolito, R.; Foresi, A.; Chetta, A.; Casalini, A.; Castagnaro, A.; Leone, C.; Olivieri, D. Induced sputum in patients with newly diagnosed sarcoidosis: comparison with bronchial wash and BAL. Chest, 1999, 115(6), 1611-1615.
330. Pizzichini, E.; Pizzichini, M.M.; Kidney, J.C.; Efthimiadis, A.; Hussack, P.; Popov, T.; Cox, G.; Dolovich, J.; O'Byrne, P.; Har-greave, F.E. Induced sputum, bronchoalveolar lavage and blood from mild asthmatics: inflammatory cells, lymphocyte subsets and soluble markers compared. Eur. Respir J., 1998, 11(4), 828-834.
331. Brightling, C.E.; Symon, F.A.; Birring, S.S.; Bradding, P.; Ward-law, A.J.; Pavord, I.D. Comparison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax, 2003, 58(6), 528-32.
332. Lundström, S.L.; Yang, Y.; Hammock, B.D.; Sköld, M.; Grune-wald, J.; Eklund, A.; Svartengren, M.; Larsson, B.-M.; Wheelock, C.E.; Wheelock, Å.M. [Unpublished Data].
333. Lee, S.H.; Blair, I.A. Targeted chiral lipidomics analysis of bioac-tive eicosanoid lipids in cellular systems. BMB Rep., 2009, 42(7), 401-410.
334. Mesaros, C.; Lee, S.H.; Blair, I.A. Targeted quantitative analysis of eicosanoid lipids in biological samples using liquid chromatogra-phy-tandem mass spectrometry. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci., 2009, 877(26), 2736-2745.
335. Kiss, L.; Bier, J.; Roder, Y.; Weissmann, N.; Grimminger, F.; See-ger, W. Direct and simultaneous profiling of epoxyeicosatrienoic acid enantiomers by capillary tandem column chiral-phase liquid chromatography with dual online photodiode array and tandem mass spectrometric detection. Anal. Bioanal. Chem., 2008, 392(4), 717-726.
336. Lee, S.H.; Williams, M.V.; Blair, I.A. Targeted chiral lipidomics analysis. Prostaglandins Other Lipid Mediat, 2005, 77(1-4), 141-157.
337. Baughman, R.P. The uncertainties of bronchoalveolar lavage. Eur. Respir. J., 1997, 10(9), 1940-1642.
338. Eriksson, L.; Johanssonn, E.; Kettaneh-Wold, N.; Wikström, C.; Wold, S. Design of Experiments: Principles and Applications. Umetrics Academy: 2000; p 320.
339. Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate. A practical and powerful approach to multiple testing. J. R. Statist Soc. B-Methodological., 1995, 57(1), 289-300.
340. Madsen, R.; Lundstedt, T.; Trygg, J. Chemometrics in metabolom-ics--a review in human disease diagnosis. Anal. Chim. Acta, 2010, 659(1-2), 23-33.
341. Trygg, J.; Holmes, E.; Lundstedt, T. Chemometrics in metabonom-ics. J. Proteome Res., 2007, 6(2), 469-479.
342. Trygg, J.; Wold, S. Orthogonal projections to latent structures (O-PLS). J. Chemometrics, 2002, 16(3), 119-128.
343. Kelder, T.; Conklin, B.R.; Evelo, C.T.; Pico, A.R. Finding the right questions: exploratory pathway analysis to enhance biological discovery in large datasets. PLoS Biol., 2010, 8(8). pii: e1000472
344. Ng, A.; Bursteinas, B.; Gao, Q.; Mollison, E.; Zvelebil, M. Resources for integrative systems biology: from data through databases to networks and dynamic system models. Brief Bioinform., 2006, 7(4), 318-330.
345. van Iersel, M.P.; Kelder, T.; Pico, A.R.; Hanspers, K.; Coort, S.; Conklin, B.R.; Evelo, C. Presenting and exploring biological pathways with PathVisio. BMC Bioinformatics, 2008, 9, 399.
346. Ekins, S.; Nikolsky, Y.; Bugrim, A.; Kirillov, E.; Nikolskaya, T. Pathway mapping tools for analysis of high content data. Methods Mol. Biol., 2007, 356, 319-350.
347. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res., 2003, 13(11), 2498-2504.
348. Junker, B.H.; Klukas, C.; Schreiber, F. VANTED: a system for advanced data analysis and visualization in the context of biological networks. BMC Bioinformatics, 2006, 7, 109.
349. Hucka, M.; Finney, A.; Sauro, H.M.; Bolouri, H.; Doyle, J.C.; Kitano, H.; Arkin, A.P.; Bornstein, B.J.; Bray, D.; Cornish-Bowden, A.; Cuellar, A.A.; Dronov, S.; Gilles, E.D.; Ginkel, M.; Gor, V.; Goryanin, II; Hedley, W.J.; Hodgman, T.C.; Hofmeyr, J.H.; Hunter, P.J.; Juty, N.S.; Kasberger, J.L.; Kremling, A.; Kum-mer, U.; Le Novere, N.; Loew, L.M.; Lucio, D.; Mendes, P.; Minch, E.; Mjolsness, E.D.; Nakayama, Y.; Nelson, M.R.; Nielsen, P.F.; Sakurada, T.; Schaff, J.C.; Shapiro, B.E.; Shimizu, T.S.; Spence, H.D.; Stelling, J.; Takahashi, K.; Tomita, M.; Wagner, J.; Wang, J. The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics, 2003, 19(4), 524-531.
350. Kanehisa, M.; Araki, M.; Goto, S.; Hattori, M.; Hirakawa, M.; Itoh, M.; Katayama, T.; Kawashima, S.; Okuda, S.; Tokimatsu, T.; Ya-manishi, Y. KEGG for linking genomes to life and the environment. Nucl. Acids Res., 2008, 36(Database issue), D480-D484.
351. Wheelock, C.E.; Goto, S.; Yetukuri, L.; D'Alexandri, F.L.; Klukas, C.; Schreiber, F.; Oresic, M. Bioinformatics strategies for the analysis of lipids. Methods Mol. Biol., 2009, 580, 339-368.
352. Gentleman, R.C.; Carey, V.J.; Bates, D.M.; Bolstad, B.; Dettling, M.; Dudoit, S.; Ellis, B.; Gautier, L.; Ge, Y.; Gentry, J.; Hornik, K.; Hothorn, T.; Huber, W.; Iacus, S.; Irizarry, R.; Leisch, F.; Li, C.; Maechler, M.; Rossini, A.J.; Sawitzki, G.; Smith, C.; Smyth, G.; Tierney, L.; Yang, J.Y.; Zhang, J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol., 2004, 5(10), R80.
353. Aoki, K.F.; Kanehisa, M. Using the KEGG database resource. Curr Protoc Bioinformatics, 2005, Chapter 1, Unit 1 12.
354. Wheelock, C.E.; Wheelock, A.M.; Kawashima, S.; Diez, D.; Kane-hisa, M.; van Erk, M.; Kleemann, R.; Haeggstrom, J.Z.; Goto, S. Systems biology approaches and pathway tools for investigating cardiovascular disease. Mol. Biosyst., 2009, 5(6), 588-602.
355. Huopaniemi, I.; Suvitaival, T.; Nikkila, J.; Oresic, M.; Kaski, S. Multivariate multi-way analysis of multi-source data. Bioinformat-ics, 2010, 26(12), i391-398.
356. Yetukuri, L.; Ekroos, K.; Vidal-Puig, A.; Oresic, M. Informatics and computational strategies for the study of lipids. Mol. Biosyst., 2008, 4(2), 121-127.
357. Connor, S.C.; Hansen, M.K.; Corner, A.; Smith, R.F.; Ryan, T.E. Integration of metabolomics and transcriptomics data to aid bio-marker discovery in type 2 diabetes. Mol. Biosyst, 2010, 6(5), 909-921.
358. Diez, D.; Wheelock, A.M.; Goto, S.; Haeggstrom, J.Z.; Paulsson-Berne, G.; Hansson, G.K.; Hedin, U.; Gabrielsen, A.; Wheelock, C.E. The use of network analyses for elucidating mechanisms in cardiovascular disease. Mol. Biosyst., 2010, 6(2), 289-304.
359. Auffray, C.; Adcock, I.M.; Chung, K.F.; Djukanovic, R.; Pison, C.; Sterk, P.J. An integrative systems biology approach to understanding pulmonary diseases. Chest, 2010, 137(6), 1410-1416.
360. Basu, S. Isoprostanes: novel bioactive products of lipid peroxida-tion. Free Radic. Res, 2004, 38(2), 105-122.